{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T19:27:41Z","timestamp":1793129261336,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T00:00:00Z","timestamp":1557792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s40262-019-00775-z","type":"journal-article","created":{"date-parts":[[2019,5,14]],"date-time":"2019-05-14T02:37:28Z","timestamp":1557801448000},"page":"1265-1279","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":329,"title":["Apixaban: A Clinical Pharmacokinetic and Pharmacodynamic Review"],"prefix":"10.1007","volume":"58","author":[{"given":"Wonkyung","family":"Byon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samira","family":"Garonzik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles E.","family":"Frost","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,14]]},"reference":[{"key":"775_CR1","unstructured":"Bristol-Myers Squibb. Coumadin (wafarin sodium) prescribing information. 2017. \n                    http:\/\/packageinserts.bms.com\/pi\/pi_coumadin.pdf\n                    \n                  . Accessed 2 Feb 2018."},{"issue":"5","key":"775_CR2","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","volume":"154","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Banerjee A, Boriani G, Chiang CE, Fargo R, Freedman B, et al. Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report. Chest. 2018;154(5):1121\u2013201.","journal-title":"Chest"},{"key":"775_CR3","unstructured":"Bristol-Myers Squibb, Pfizer EEIG. EU summary of product characteristics: Eliquis (apixaban tablets). 2018. \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf\n                    \n                  . Accessed 8 Apr 2019."},{"key":"775_CR4","unstructured":"Bristol-Myers Squibb Company PI. Eliquis (apixaban) prescribing information. 2018. \n                    http:\/\/packageinserts.bms.com\/pi\/pi_eliquis.pdf\n                    \n                  . Accessed 14 Jun 2018."},{"issue":"11","key":"775_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek E, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981\u201392.","journal-title":"N Engl J Med"},{"issue":"9","key":"775_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364(9):806\u201317.","journal-title":"N Engl J Med"},{"issue":"9717","key":"775_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","volume":"375","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet. 2010;375(9717):807\u201315.","journal-title":"Lancet"},{"issue":"26","key":"775_CR8","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","volume":"363","author":"MR Lassen","year":"2010","unstructured":"Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med. 2010;363(26):2487\u201398.","journal-title":"N Engl J Med"},{"issue":"6","key":"775_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1056\/NEJMoa0810773","volume":"361","author":"MR Lassen","year":"2009","unstructured":"Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med. 2009;361(6):594\u2013604.","journal-title":"N Engl J Med"},{"issue":"9","key":"775_CR10","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","volume":"369","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799\u2013808.","journal-title":"N Engl J Med"},{"issue":"8","key":"775_CR11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1207541","volume":"368","author":"G Agnelli","year":"2013","unstructured":"Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med. 2013;368(8):699\u2013708.","journal-title":"N Engl J Med"},{"issue":"22","key":"775_CR12","doi-asserted-by":"publisher","first-page":"5339","DOI":"10.1021\/jm070245n","volume":"50","author":"DJ Pinto","year":"2007","unstructured":"Pinto DJ, Orwat MJ, Koch S, Rossi KA, Alexander RS, Smallwood A, et al. Discovery of 1-(4-methoxyphenyl)-7-oxo-6-(4-(2-oxopiperidin-1-yl)phenyl)-4,5,6,7-tetrahydro-1H-pyrazolo[3,4-c]pyridine-3-carboxamide (apixaban, BMS-562247), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. J Med Chem. 2007;50(22):5339\u201356.","journal-title":"J Med Chem"},{"issue":"4","key":"775_CR13","doi-asserted-by":"publisher","first-page":"514","DOI":"10.3109\/14756366.2010.535793","volume":"26","author":"JM Luettgen","year":"2011","unstructured":"Luettgen JM, Knabb RM, He K, Pinto DJ, Rendina AR. Apixaban inhibition of factor Xa: microscopic rate constants and inhibition mechanism in purified protein systems and in human plasma. J Enzyme Inhib Med Chem. 2011;26(4):514\u201326.","journal-title":"J Enzyme Inhib Med Chem"},{"issue":"Suppl. 1","key":"775_CR14","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/j.1538-7836.2007.02473.x","volume":"5","author":"J Ansell","year":"2007","unstructured":"Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007;5(Suppl. 1):60\u20134.","journal-title":"J Thromb Haemost"},{"issue":"4","key":"775_CR15","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1160\/TH08-07-0486","volume":"101","author":"X Jiang","year":"2009","unstructured":"Jiang X, Crain EJ, Luettgen JM, Schumacher WA, Wong PC. Apixaban, an oral direct factor Xa inhibitor, inhibits human clot-bound factor Xa activity in vitro. Thromb Haemost. 2009;101(4):780\u20132.","journal-title":"Thromb Haemost"},{"issue":"4","key":"775_CR16","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s11239-011-0551-3","volume":"31","author":"PC Wong","year":"2011","unstructured":"Wong PC, Pinto DJ, Zhang D. Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011;31(4):478\u201392.","journal-title":"J Thromb Thrombolysis"},{"issue":"2","key":"775_CR17","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1111\/j.1365-2125.2012.04369.x","volume":"75","author":"C Frost","year":"2013","unstructured":"Frost C, Wang J, Nepal S, Schuster A, Barrett YC, Mosqueda-Garcia R, et al. Apixaban, an oral, direct factor Xa inhibitor: single-dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol. 2013;75(2):476\u201387.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"775_CR18","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1124\/dmd.108.023143","volume":"37","author":"N Raghavan","year":"2009","unstructured":"Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37(1):74\u201381.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"775_CR19","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1124\/dmd.108.025981","volume":"37","author":"D Zhang","year":"2009","unstructured":"Zhang D, He K, Raghavan N, Wang L, Mitroka J, Maxwell BD, et al. Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans. Drug Metab Dispos. 2009;37(8):1738\u201348.","journal-title":"Drug Metab Dispos"},{"issue":"15","key":"775_CR20","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.4155\/bio.14.66","volume":"6","author":"J Pursley","year":"2014","unstructured":"Pursley J, Shen JX, Schuster A, Dang OT, Lehman J, Buonarati MH, et al. LC-MS\/MS determination of apixaban (BMS-562247) and its major metabolite in human plasma: an application of polarity switching and monolithic HPLC column. Bioanalysis. 2014;6(15):2071\u201382.","journal-title":"Bioanalysis."},{"issue":"5","key":"775_CR21","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1111\/bcp.12106","volume":"76","author":"C Frost","year":"2013","unstructured":"Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013;76(5):776\u201386.","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"775_CR22","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/jcph.1097","volume":"58","author":"W Byon","year":"2018","unstructured":"Byon W, Nepal S, Schuster AE, Shenker A, Frost CE. Regional gastrointestinal absorption of apixaban in healthy subjects. J Clin Pharmacol. 2018;58(7):965\u201371.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"775_CR23","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40256-015-0157-9","volume":"16","author":"B Vakkalagadda","year":"2016","unstructured":"Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of rifampin on the pharmacokinetics of apixaban, an oral direct inhibitor of factor Xa. Am J Cardiovasc Drugs. 2016;16(2):119\u201327.","journal-title":"Am J Cardiovasc Drugs."},{"key":"775_CR24","first-page":"1132","volume":"48","author":"C Frost","year":"2008","unstructured":"Frost C, Yu Z, Nepal S, Bragat A, Moore K, Shenker A, et al. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation [abstract 148]. J Clin Pharmacol. 2008;48:1132.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"775_CR25","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1124\/dmd.109.029694","volume":"38","author":"L Wang","year":"2010","unstructured":"Wang L, Zhang D, Raghavan N, Yao M, Ma L, Frost CE, et al. In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. Drug Metab Dispos. 2010;38(3):448\u201358.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"775_CR26","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1124\/dmd.112.050260","volume":"41","author":"D Zhang","year":"2013","unstructured":"Zhang D, He K, Herbst J, Kolb J, Shou W, Wang L, et al. Characterization of efflux transporters involved in distribution and disposition of apixaban. Drug Metab Dispos. 2013;41(4):827\u201335.","journal-title":"Drug Metab Dispos"},{"issue":"7","key":"775_CR27","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1016\/j.clinthera.2016.05.004","volume":"38","author":"Y Song","year":"2016","unstructured":"Song Y, Chang M, Suzuki A, Frost RJ, Kelly A, LaCreta F, et al. Evaluation of crushed tablet for oral administration and the effect of food on apixaban pharmacokinetics in healthy adults. Clin Ther. 2016;38(7):1674\u201385.","journal-title":"Clin Ther"},{"issue":"8","key":"775_CR28","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1016\/j.clinthera.2015.05.497","volume":"37","author":"Y Song","year":"2015","unstructured":"Song Y, Wang X, Perlstein I, Wang J, Badawy S, Frost C, et al. Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. Clin Ther. 2015;37(8):1703\u201312.","journal-title":"Clin Ther"},{"issue":"Suppl. 1","key":"775_CR29","first-page":"S120","volume":"93","author":"Y Song","year":"2013","unstructured":"Song Y, Worthington J, Wang X. Development of apixaban oral solution formulation: excipients and palatability. Clin Pharmacol Ther. 2013;93(Suppl. 1):S120\u20131.","journal-title":"Clin Pharmacol Ther."},{"issue":"3","key":"775_CR30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s13318-011-0037-x","volume":"36","author":"K He","year":"2011","unstructured":"He K, Luettgen JM, Zhang D, He B, Grace JE Jr, Xin B, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet. 2011;36(3):129\u201339.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"5","key":"775_CR31","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1002\/jcph.628","volume":"56","author":"X Wang","year":"2016","unstructured":"Wang X, Tirucherai G, Marbury TC, Wang J, Chang M, Zhang D, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis. J Clin Pharmacol. 2016;56(5):628\u201336.","journal-title":"J Clin Pharmacol"},{"key":"775_CR32","unstructured":"Frost C, Yu Z, Wang J, Li T, Ziegler C, Schuster A, et al. Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. Clin Pharmacol Ther. 2009;85(Suppl. 1):S34."},{"issue":"2","key":"775_CR33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1124\/dmd.110.036442","volume":"39","author":"L Wang","year":"2011","unstructured":"Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, et al. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos. 2011;39(2):256\u201364.","journal-title":"Drug Metab Dispos"},{"key":"775_CR34","first-page":"153","volume":"10","author":"C Frost","year":"2018","unstructured":"Frost C, Shenker A, Jhee S, Yu Z, Wang J, Bragat A, et al. Evaluation of the single-dose pharmacokinetics and pharmacodynamics of apixaban in healthy Japanese and Caucasian subjects. Clin Pharmacol. 2018;10:153\u201363.","journal-title":"Clin Pharmacol."},{"issue":"7","key":"775_CR35","first-page":"564","volume":"52","author":"N Yamahira","year":"2014","unstructured":"Yamahira N, Frost C, Fukase H, Yu Z, Wang J, Pursley J, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of apixaban in healthy Japanese male subjects. Int J Clin Pharmacol Ther. 2014;52(7):564\u201373.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"775_CR36","first-page":"177","volume":"5","author":"Y Cui","year":"2013","unstructured":"Cui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol. 2013;5:177\u201384.","journal-title":"Clin Pharmacol."},{"issue":"2","key":"775_CR37","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40256-013-0055-y","volume":"14","author":"X Wang","year":"2014","unstructured":"Wang X, Mondal S, Wang J, Tirucherai G, Zhang D, Boyd RA, et al. Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. Am J Cardiovasc Drugs. 2014;14(2):147\u201354.","journal-title":"Am J Cardiovasc Drugs."},{"issue":"5","key":"775_CR38","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1002\/jcph.447","volume":"55","author":"C Frost","year":"2015","unstructured":"Frost C, Nepal S, Byon W, Moore K, Reeves RA, Boyd R, et al. Randomized, blinded, placebo- and positive-controlled crossover study to determine the effect of multiple doses of apixaban on the QTc interval. J Clin Pharmacol. 2015;55(5):549\u201355.","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"775_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/s40262-014-0228-0","volume":"54","author":"CE Frost","year":"2015","unstructured":"Frost CE, Song Y, Shenker A, Wang J, Barrett YC, Schuster A, et al. Effects of age and sex on the single-dose pharmacokinetics and pharmacodynamics of apixaban. Clin Pharmacokinet. 2015;54(6):651\u201362.","journal-title":"Clin Pharmacokinet"},{"key":"775_CR40","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1038\/psp.2014.34","volume":"3","author":"TA Leil","year":"2014","unstructured":"Leil TA, Frost C, Wang X, Pfister M, LaCreta F. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery. CPT Pharmacometrics Syst Pharmacol. 2014;3:e136.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"5","key":"775_CR41","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/psp4.12184","volume":"6","author":"W Byon","year":"2017","unstructured":"Byon W, Sweeney K, Frost C, Boyd R. Population pharmacokinetics, pharmacodynamics, and exploratory exposure-response analyses of apixaban in subjects treated for venous thromboembolism. CPT Pharmacometrics Syst Pharmacol. 2017;6(5):340\u20139.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"11","key":"775_CR42","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1002\/psp4.12347","volume":"7","author":"B Cirincione","year":"2018","unstructured":"Cirincione B, Kowalski K, Nielsen J, Roy A, Thanneer N, Byon W, et al. Population pharmacokinetics of apixaban in subjects with non-valvular atrial fibrillation. CPT Pharmacometrics Syst Pharmacol. 2018;7(11):728\u201338.","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"28","key":"775_CR43","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1093\/eurheartj\/ehu046","volume":"35","author":"S Halvorsen","year":"2014","unstructured":"Halvorsen S, Atar D, Yang H, De Caterina R, Erol C, Garcia D, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35(28):1864\u201372.","journal-title":"Eur Heart J"},{"issue":"3","key":"775_CR44","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/jth.12109","volume":"11","author":"GF Pineo","year":"2013","unstructured":"Pineo GF, Gallus AS, Raskob GE, Chen D, Ramirez LM, Ramacciotti E, et al. Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups. J Thromb Haemost. 2013;11(3):444\u201351.","journal-title":"J Thromb Haemost"},{"issue":"1","key":"775_CR45","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/ageing\/afv156","volume":"45","author":"KH Ng","year":"2016","unstructured":"Ng KH, Shestakovska O, Connolly SJ, Eikelboom JW, Avezum A, Diaz R, et al. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. Age Ageing. 2016;45(1):77\u201383.","journal-title":"Age Ageing"},{"issue":"6","key":"775_CR46","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/bcp.12114","volume":"76","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of apixaban in healthy subjects. Br J Clin Pharmacol. 2013;76(6):908\u201316.","journal-title":"Br J Clin Pharmacol"},{"issue":"38","key":"775_CR47","doi-asserted-by":"publisher","first-page":"2869","DOI":"10.1093\/eurheartj\/ehw124","volume":"37","author":"RK Sandhu","year":"2016","unstructured":"Sandhu RK, Ezekowitz J, Andersson U, Alexander JH, Granger CB, Halvorsen S, et al. The \u2018obesity paradox\u2019 in atrial fibrillation: observations from the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. Eur Heart J. 2016;37(38):2869\u201378.","journal-title":"Eur Heart J"},{"issue":"9","key":"775_CR48","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1097\/FPC.0000000000000294","volume":"27","author":"S Ueshima","year":"2017","unstructured":"Ueshima S, Hira D, Fujii R, Kimura Y, Tomitsuka C, Yamane T, et al. Impact of ABCB1, ABCG2, and CYP3A5 polymorphisms on plasma trough concentrations of apixaban in Japanese patients with atrial fibrillation. Pharmacogenet Genomics. 2017;27(9):329\u201336.","journal-title":"Pharmacogenet Genomics"},{"issue":"6","key":"775_CR49","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1111\/bcp.13561","volume":"84","author":"S Ueshima","year":"2018","unstructured":"Ueshima S, Hira D, Kimura Y, Fujii R, Tomitsuka C, Yamane T, et al. Population pharmacokinetics and pharmacogenomics of apixaban in Japanese adult patients with atrial fibrillation. Br J Clin Pharmacol. 2018;84(6):1301\u201312.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"775_CR50","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.ahj.2014.06.005","volume":"168","author":"S Goto","year":"2014","unstructured":"Goto S, Zhu J, Liu L, Oh BH, Wojdyla DM, Aylward P, et al. Efficacy and safety of apixaban compared with warfarin for stroke prevention in patients with atrial fibrillation from East Asia: a subanalysis of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Trial. Am Heart J. 2014;168(3):303\u20139.","journal-title":"Am Heart J"},{"issue":"5","key":"775_CR51","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1002\/jcph.633","volume":"56","author":"M Chang","year":"2016","unstructured":"Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin Pharmacol. 2016;56(5):637\u201345.","journal-title":"J Clin Pharmacol"},{"key":"775_CR52","unstructured":"Stanifer J, Chertow G, Hohnloser S, Wojdyla D, Garoznik S, Byon W, et al. Apixaban versus warfarin in patients with atrial fibrillation and stage 4 chronic kidney disease. J Am Soc Nephrol. 2017;28(Suppl. 1):218. \n                    https:\/\/www.asn-online.org\/education\/kidneyweek\/2017\/program-abstract.aspx?controlId=2787114\n                    \n                  . Accessed 6 May 2019."},{"issue":"2","key":"775_CR53","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jacc.2010.09.024","volume":"57","author":"GY Lip","year":"2011","unstructured":"Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal\/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs\/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011;57(2):173\u201380.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"775_CR54","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1124\/dmd.117.079624","volume":"46","author":"RG Tirona","year":"2018","unstructured":"Tirona RG, Kassam Z, Strapp R, Ramu M, Zhu C, Liu M, et al. Apixaban and rosuvastatin pharmacokinetics in nonalcoholic fatty liver disease. Drug Metab Dispos. 2018;46(5):485\u201392.","journal-title":"Drug Metab Dispos"},{"key":"775_CR55","unstructured":"Perlstein I, Suryawanshi S, Elefant E, Wang Z, Cohen L, Abu Tarif M, et al. Multiple-dose study to evaluate apixaban pharmacokinetics, pharmacodynamics, safety, and tolerability in pediatric subjects with an indwelling central venous catheter. Clin Pharmacol Ther. 2014;95(Suppl.):S61\u20132."},{"key":"775_CR56","first-page":"19","volume":"9","author":"C Frost","year":"2017","unstructured":"Frost C, Song Y, Yu Z, Wang J, Lee LS, Schuster A, et al. The effect of apixaban on the pharmacokinetics of digoxin and atenolol in healthy subjects. Clin Pharmacol. 2017;9:19\u201328.","journal-title":"Clin Pharmacol."},{"issue":"1","key":"775_CR57","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1208\/s12248-014-9668-6","volume":"17","author":"Q Mao","year":"2015","unstructured":"Mao Q, Unadkat JD. Role of the breast cancer resistance protein (BCRP\/ABCG2) in drug transport: an update. AAPS J. 2015;17(1):65\u201382.","journal-title":"AAPS J"},{"issue":"5","key":"775_CR58","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/bcp.12541","volume":"79","author":"CE Frost","year":"2015","unstructured":"Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015;79(5):838\u201346.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"775_CR59","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1111\/bcp.12393","volume":"78","author":"C Frost","year":"2014","unstructured":"Frost C, Shenker A, Gandhi MD, Pursley J, Barrett YC, Wang J, et al. Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. Br J Clin Pharmacol. 2014;78(4):877\u201385.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"775_CR60","first-page":"59","volume":"5","author":"VV Upreti","year":"2013","unstructured":"Upreti VV, Song Y, Wang J, Byon W, Boyd RA, Pursley JM, et al. Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Clin Pharmacol. 2013;5(1):59\u201366.","journal-title":"Clin Pharmacol."},{"issue":"5","key":"775_CR61","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1177\/1076029612441859","volume":"19","author":"YC Barrett","year":"2013","unstructured":"Barrett YC, Wang Z, Knabb RM. A novel prothrombin time assay for assessing the anticoagulant activity of oral factor Xa inhibitors. Clin Appl Thromb Hemost. 2013;19(5):522\u20138.","journal-title":"Clin Appl Thromb Hemost"},{"issue":"11","key":"775_CR62","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1111\/jth.13815","volume":"15","author":"Y Song","year":"2017","unstructured":"Song Y, Wang Z, Perlstein I, Wang J, LaCreta F, Frost RJA, et al. Reversal of apixaban anticoagulation by 4-factor prothrombin complex concentrates in healthy subjects: a randomized 3-period crossover study. J Thromb Haemost. 2017;15(11):2125\u201337.","journal-title":"J Thromb Haemost"},{"issue":"8","key":"775_CR63","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1160\/TH16-06-0423","volume":"117","author":"RJ Yetman","year":"2017","unstructured":"Yetman RJ, Barrett YC, Wang Z, Adamczyk R, Wang J, Ramacciotti E, et al. Apixaban pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. Thromb Haemost. 2017;117(8):1518\u201327.","journal-title":"Thromb Haemost"},{"issue":"5","key":"775_CR64","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1160\/TH11-09-0634","volume":"107","author":"YC Barrett","year":"2012","unstructured":"Barrett YC, Wang J, Song Y, Pursley J, Wastall P, Wright R, et al. A randomised assessment of the pharmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost. 2012;107(5):916\u201324.","journal-title":"Thromb Haemost"},{"issue":"Suppl. 1","key":"775_CR65","first-page":"29","volume":"3","author":"C Frost","year":"2014","unstructured":"Frost C, Yu Z, Wastall P, Nepal S, Moore K, Shenker A, et al. Tolerability, pharmacokinetics, and pharmacodynamics of apixaban, aspirin, and clopidogrel following coadministration in healthy subjects. Clin Pharmacol Drug Dev. 2014;3(Suppl. 1):29\u201330.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"Suppl. 1","key":"775_CR66","first-page":"30","volume":"3","author":"M AbuTariff","year":"2014","unstructured":"AbuTariff M, Bui A, Pursley J, He J, La Creta F, Frost C. Lack of pharmacokinetic interaction between apixaban and prasugrel in healthy subjects. Clin Pharmacol Drug Dev. 2014;3(Suppl. 1):30\u20131.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"3","key":"775_CR67","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/clpt.2010.106","volume":"88","author":"TA Leil","year":"2010","unstructured":"Leil TA, Feng Y, Zhang L, Paccaly A, Mohan P, Pfister M. Quantification of apixaban\u2019s therapeutic utility in prevention of venous thromboembolism: selection of phase III trial dose. Clin Pharmacol Ther. 2010;88(3):375\u201382.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"775_CR68","first-page":"1263","volume":"104","author":"YC Barrett","year":"2010","unstructured":"Barrett YC, Wang Z, Frost C, Shenker A. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104(6):1263\u201371.","journal-title":"Thromb Haemost"},{"issue":"8","key":"775_CR69","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cjca.2017.04.008","volume":"33","author":"M Gulilat","year":"2017","unstructured":"Gulilat M, Tang A, Gryn SE, Leong-Sit P, Skanes AC, Alfonsi JE, et al. Interpatient variation in rivaroxaban and apixaban plasma concentrations in routine care. Can J Cardiol. 2017;33(8):1036\u201343.","journal-title":"Can J Cardiol"},{"key":"775_CR70","unstructured":"Portola Pharmaceuticals. Andexxa [prescribing information]. 2018. \n                    https:\/\/www.andexxa.com\/prescribing-information\/\n                    \n                  . Accessed 8 Apr 2019."},{"issue":"25","key":"775_CR71","doi-asserted-by":"publisher","first-page":"2413","DOI":"10.1056\/NEJMoa1510991","volume":"373","author":"DM Siegal","year":"2015","unstructured":"Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med. 2015;373(25):2413\u201324.","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"775_CR72","first-page":"30","volume":"11","author":"M Crowther","year":"2013","unstructured":"Crowther M, Kitt M, Lorenz T, Mathur V, Lu G, Hutchaleelaha A, et al. A phase 2 randomized, double-blind, placebo-controlled trial of PRT064445, a novel, universal antidote for direct and indirect factor Xa inhibitors [abstract]. J Thromb Haemost. 2013;11(Suppl. 2):30.","journal-title":"J Thromb Haemost"},{"issue":"12","key":"775_CR73","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1056\/NEJMoa1607887","volume":"375","author":"SJ Connolly","year":"2016","unstructured":"Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375(12):1131\u201341.","journal-title":"N Engl J Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-019-00775-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-019-00775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T19:15:03Z","timestamp":1589310903000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-019-00775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,14]]},"references-count":73,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1007\/s40262-019-00775-z","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,14]]},"assertion":[{"value":"14 May 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This study was funded by Bristol-Myers Squibb and Pfizer Inc. Rob Coover, MPH, and Claire Line, PhD, employees of Caudex, provided editorial assistance, and this assistance was funded by Bristol-Myers Squibb and Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Wonkyung Byon and Rebecca A. Boyd are current or former employees of Pfizer, Inc., and own stock\/stock options. Samira Garonzik is an employee of Bristol-Myers Squibb. Charles E. Frost is an employee of, owns stock\/stock options in, has received travel support and payment for lectures from, and is an inventor on patents with Bristol-Myers Squibb.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}